



ABN 13 009 607 676
246 Esplanade
Brighton Vic 3186
Australia
Phone 613 9553 8896
Fax 613 9592 2328
admin@plentex.com.au

20 February 2015

ASX ANNOUNCEMENT

Acquisition of Biovite Australia Pty. Ltd.

The Directors of Plentex Limited are pleased to advise that one of its subsidiaries, Xerion Limited ("Xerion") has, after many months of negotiation, acquired Biovite Australia Pty. Ltd. ("Biovite") and has assumed management control of the Company.

Biovite has a versatile proprietary algae based bioactive Amycot® which has anti-fungal, anti-bacterial, anti-inflammatory, anti-viral and skin repair properties. Biovite has a range of topical anti-fungal products sold under the Calmagen® brand which are available as over-the-counter products in Australia and sold in Germany, Taiwan and Malaysia with over 400,000 units sold to date.

Plentex Directors, Peter Streader and Danny Goldman, and Xerion's Chief Scientific Officer, Dr. Vic Ilag, have been appointed as Directors of Biovite Australia Pty. Ltd. Consideration for the purchase consists of a mix of cash payable in instalments totalling \$3,000,000, and the issue to the Biovite shareholder vendors of 6,500,000 fully paid ordinary shares in Xerion and 2,500,000 Performance Shares and subject to Plentex shareholder approval, 1,500,000 fully paid ordinary shares in Plentex.

An initial deposit of \$50,000 has been paid with the balance of deposit (\$450,000) due on 17 June 2015. The balance of the purchase price (\$2,500,000) is payable on or before 17 February 2017.

The Xerion Performance Shares have been issued on the basis that they will convert into fully paid ordinary shares if within 24 months of the date of their issue, Xerion is successful in concluding the licensing of any product which contains or is to contain Biovite Australia's key bioactive product Amycot® or any derivative thereof or Xerion licenses its Dried Blood Spot sampling technique which results in consideration being payable to Xerion either as an upfront licence payment or guaranteed cumulative consideration payable by the licensee to Xerion exceeding \$4 million on a tiered conversion basis, depending on the cumulative consideration payable pursuant to an agreed licensing arrangement.

This event of conversion is to apply once only and in the event that any one of the above milestones is not achieved by the expiration of the 24 month period, the Performance Shares will lapse.

Xerion is currently completing a second seed capital raising of \$250,000 at an issue price of 15 cents a share and plans to raise a further \$2.7 million by way of an Offer Information Statement at 20 cents a share commencing in late March 2015.

Xerion has engaged Melbourne based Sanston Securities Australia Pty. Ltd. as Corporate Financial advisor to the offer to assist Xerion with the \$2.7 million capital raising.

Plentex hold 6,010,000 fully paid ordinary shares in Xerion together with 3,000,000 options exercisable at 30 cents at any time prior to 31 December 2016.

The capital structure of Xerion following the completion of the current seed capital raising will be as follows:

Shareholders	No. of Shares	% Shareholding
Plentex Limited	6,010,000	33.3%
Other shareholders	3,878,000	21.5%
Seed Investors @ 15c.	1,666,667	9.2%
Shareholders - Biovite Australia Pty. Ltd.	6,500,000	36.0%
Total	18,054,667	100.0%

Optionholders ⁽¹⁾	No. of Options	% Options
Plentex Limited	3,000,000	65.6%
Other optionholders	1,577,999	34.4%
Total	4,577,999	100.0%

Performance Shares

Shareholders - Biovite Australia Pty. Ltd.	2,500,000	100.0%
--	------------------	---------------

Notes:

- (1) These options are exercisable at 30 cents at any time prior to 31 December 2016.
- (2) Subject to the successful completion of the \$2.7 million capital raising referred to above, Xerion will issue up to a further 3,155,467 options exercisable at 30 cents at any time prior to 31 December 2019.

With the acquisition of Biovite, Xerion now has 3 significant platforms to enhance its business growth:

1. An existing range of Australian Therapeutic Goods Administration (TGA) approved anti-fungal products that are already being sold in Australia and some offshore markets which currently generate cashflow. With a new professional marketing campaign and distribution strategy, Xerion expects sales to grow significantly.
2. An exciting new medical device/companion diagnostic tool that is market ready to generate substantial sales. This tool allows for a different way to collect blood in a cost effective manner and is perfectly suited to the mass market and has the potential to disrupt certain aspects of the existing labour intensive process for the collection of blood.
3. A portfolio of projects that are in various stages of research and/or development that will bring new naturally based algae products to the market in a controlled manner.

Xerion's short-term objectives will be to expand the Calmagen® product line and boost sales and distribution. Xerion has appointed an internationally recognised marketing organisation SPRIM to investigate licensing opportunities, assist with the relaunch of the Biovite range of products, implementation of a digital marketing strategy including e-commerce capability and the appointment of additional local and international distributors. The product range will be launched in Canada in the second half of 2015. New products may be developed to treat acne, atopic dermatitis and other skin conditions using the AMYCOT® platform.

The market for fungal products is very large. Fungal infections of the skin and nails are a health concern worldwide affecting an estimated 10-20% of the global population. Biovite's Calmagen® product is very effective because it kills fungal spores unlike most existing products in the market which do not kill the fungi but only inhibit future growth. Most of these other products are chemically based and can have unwanted side effects. Naturally-based Calmagen® offers a safe and highly efficacious alternative that has been validated in multiple clinical trials.

Some months ago, Xerion acquired the worldwide exclusive commercial rights to the only Dried Blood Spot (DBS) technology that accurately measures fatty acids in blood and other biological fluids such as breast milk. The technology was developed by Prof. Robert Gibson from the University of Adelaide, a leading world authority in nutrition. It is currently being used in a clinical trial testing 5,500 pregnant mothers and in another trial testing 1,225 infants.

This technology has the potential in revolutionizing aspects of the personalised medicine/nutrition space by offering a robust companion diagnostic. Xerion will explore its immediate applications in determining the Omega 3 Index, an emerging therapeutic indicator and other fatty acid profiles which are good biomarkers for cardiovascular health, inflammation and cognitive health. The Company anticipates immediate revenues from the technology by selling it as a research tool in biomarker discovery and clinical trials. Other future revenue streams from the technology are currently under discussion.

Through its acquisition last year of Plentex's portfolio of algae based projects and related intellectual property, the focus of which was to develop a range of natural efficacious algae derived products, Xerion has access to novel algal strains and proprietary extraction methods that could feed a robust product pipeline. Xerion also has high valued research partnerships which will be key in expanding its algal based product platforms.

Whilst considerable effort has been directed by Plentex in developing Xerion's business to this point, we are pleased to report that Plentex's aquafeed projects in the Philippines and South Australia have also been rapidly advanced over the past few months.

We have established new subsidiaries, Plentex Philippines Inc. (incorporated in the Philippines) and Protemax Pty. Ltd. as the corporate vehicles for these projects. Further development of these projects will require the raising of funds and the restructuring of Plentex's current issued capital.

To facilitate this capital raising and address other ancillary matters, Plentex is preparing to convene a General Meeting of its shareholders.

The resolutions to be put to shareholders are being framed to provide for a two stage capital raising, the first comprising of an offer of shares to exempt investors as defined in the Corporations Act 2001, and the second by way of an offering under a prospectus on a basis which will allow the Company to seek the requote of its securities on the ASX. This offer will include provision for a priority offer to Plentex shareholders.

Plentex expects to issue a Notice of General Meeting and attaching Explanatory Memorandum shortly, which will contain appropriate details relating to these matters.

**For and on behalf of
PLENTEX LIMITED**



PETER C. STREADER
Executive Chairman

For further information contact:

Peter Streader
Executive Chairman
Plentex Limited
Telephone: +613 9553 8896
Email: admin@plentex.com.au